Is your portfolio ready? ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | A message from Interactive Offers This public company's one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market
Imagine a drug that could treat VIRUSES— such as RSV, COVID-19, Influenza, Bird Flu, Monkey Pox, and more.
We might not have to imagine it much longer. This company's leading drug candidate could completely transform the way viruses and their variants are treated worldwide. To put it simply, NV-387 could revolutionize antiviral treatment just as antibiotics did against bacteria.
There is a significant unmet medical need for a broad-spectrum antiviral drug that is effective and useable in all segments of the population— from pediatric to elderly patients. Not only this, but this innovative approach can work even when viruses mutate.
With its ongoing expansion and development of its diverse and promising product pipeline, this biotech is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
The world is changing and so are our viruses. Learn more about the company that could largely benefit your bottom line, as well as the health of our global population.
This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $4,500 for multiple Dedicated Email Sends, Newsletter Sponsorship, and SMS sends between January 10, 2024 and January 16, 2024. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
| | |
|
No comments:
Post a Comment